RAPGEFL1 Inhibitors
RAPGEFL1 inhibitors like Forskolin are known to directly stimulate adenylyl cyclase, leading to an increase in cAMP and subsequent modulation of signaling cascades that may involve RAPGEFL1. This action can have a regulatory effect on RAPGEFL1 by adjusting the cellular context in which it operates.
Inhibitors of phosphodiesterase such as Rolipram, Cilostamide, and Methylxanthines, including Caffeine, prevent the breakdown of cAMP, thereby sustaining enhanced levels of this cyclic nucleotide and potentially influencing RAPGEFL1 activity. In contrast, SQ22536 serves to decrease cAMP by inhibiting adenylyl cyclase, which could lead to the attenuation of RAPGEFL1-related signaling. Protein kinase A (PKA) inhibitors like H-89 and KT5720 can interfere with the downstream effects of cAMP, thus modifying the signaling pathways RAPGEFL1 is involved in. Such alterations in signal transduction can have a significant impact on the cellular role of RAPGEFL1. The use of these inhibitors provides insights into the mechanistic pathways of RAPGEFL1 and offers a methodological approach to regulate its activity within cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase inhibitor, increases cAMP by preventing its breakdown, possibly affecting RAPGEFL1 function. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
Adenylyl cyclase inhibitor, reduces cAMP synthesis and can alter RAPGEFL1-dependent signaling pathways. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
Protein kinase A inhibitor, can disrupt downstream effects of RAPGEFL1-mediated cAMP production. | ||||||
Rp-cAMPS | 151837-09-1 | sc-24010 | 1 mg | $203.00 | 37 | |
cAMP analog that competitively inhibits cAMP-dependent processes, potentially affecting RAPGEFL1. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
Protein kinase A inhibitor, which can disrupt processes modulated by RAPGEFL1. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Phosphodiesterase 3 inhibitor, can indirectly affect RAPGEFL1 activity by modulating cAMP levels. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
Adenosine A2A receptor antagonist, can modulate cAMP production, impacting RAPGEFL1 signaling. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Non-selective phosphodiesterase inhibitors, increase cAMP and can influence RAPGEFL1 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor, can raise cAMP levels affecting RAPGEFL1 signaling. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Phosphodiesterase inhibitor, can increase cAMP and modulate RAPGEFL1-mediated pathways. | ||||||